SCHEMBL5568069

SCHEMBL5568069

Cc1cccc2c(Nc3ccc(Cl)cc3)ncnc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.56
JAK1 P23458 1/20 0.56
TTBK1 Q5TCY1 2/20 0.51
TTBK2 Q6IQ55 2/20 0.51
MKNK1 Q9BUB5 1/20 0.50
KDM4E B2RXH2 3/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 2/20 0.49
FLT1 P17948 1/20 0.49
KDR P35968 1/20 0.49
LMNA P02545 1/20 0.49
GLA P06280 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
POLB P06746 1/20 0.48
MAPK1 P28482 1/20 0.48
AURKA O14965 1/20 0.46
RPS6KB1 P23443 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569470 0.86 EGFR (0.58) TTBK1TTBK2KDM4EALDH1A1KDR
SCHEMBL5568231 0.86 EGFR (0.64) TTBK1TTBK2MKNK1KDM4EKMT2A
SCHEMBL5570053 0.85 HPGD (0.52) TTBK1TTBK2KDM4EKMT2AMEN1
SCHEMBL5569113 0.85 EGFR (0.53) TTBK1TTBK2MKNK1KDM4EKMT2A
SCHEMBL5569346 0.85 CCNT1 (0.50) JAK2JAK1KDM4EALDH1A1LMNA
SCHEMBL5565322 0.85 AURKA (0.52) KDRNPC1RAB9AAURKARPS6KB1
SCHEMBL5564578 0.85 MAPT (0.55) LMNANPC1RAB9AAURKARPS6KB1
SCHEMBL5568284 0.84 KDM4E (0.53) KDM4EKMT2AMEN1ALDH1A1FLT1
SCHEMBL9214074 0.83 EGFR (0.64) JAK2JAK1TTBK1TTBK2MKNK1
SCHEMBL9204898 0.82 JAK2 (0.56) JAK2JAK1TTBK1TTBK2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT JAK2 1615/4885JAK1 532/4885TTBK1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.